ARTICLE | Company News

NICE draft recommends Olysio for some HCV patients

September 18, 2014 1:14 AM UTC

The U.K.'s NICE issued draft Olysio simeprevir from Medivir AB (SSE:MVIR B) and Johnson & Johnson (NYSE:JNJ) in combination with peginterferon alfa and ribavirin to treat HCV genotype 1 infection.

The committee did not recommend using Olysio to treat chronic HCV genotype 4 infection, and requested that the drug's owners demonstrate whether its effectiveness in genotype 1 patients can be generalized to include genotype 4. ...